TABLE 1.
Prevention of S. aureus infection with RIP-coated Dacron grafts in the presence or absence of parenteral antibiotic prophylaxis
| Antibiotic(s) | Bacterial concn (log CFU/ml [mean ± SD])a
|
|
|---|---|---|
| MRSA | MSSA | |
| Control (untreated) | 7.73 ± 0.11 | 7.49 ± 0.07 |
| RIP | 4.58 ± 0.09b,c | 4.64 ± 0.06b,c |
| Cefazolin | 7.49 ± 0.04 | 5.64 ± 0.25b,d |
| Cefazolin + RIP | 4.40 ± 0.09b,d | 3.40 ± 0.13b,d |
| Teicoplanin | 2.90 ± 0.05b | 1.93 ± 0.03b |
| Teicoplanin + RIP | <1b,e,f | <1b,e,f |
| Imipenem | 4.91 ± 0.19b | 3.89 ± 0.12b |
| Imipenem + RIP | 3.84 ± 0.09b | 2.86 ± 0.09b |
| Levofloxacin | 5.84 ± 0.13b | 4.59 ± 0.16b |
| Levofloxacin + RIP | 4.68 ± 0.06b,g | 3.69 ± 0.08b,g |
a
n = 15 rats per group.
b
P < 0.05 versus the control (untreated group).
c
P < 0.05 versus cefazolin treatment (MRSA) and teicoplanin treatment.
d
P < 0.05 versus cefazolin treatment.
e
P < 0.05 versus teicoplanin treatment.
f
P < 0.05 versus lerofloxacin-RIP treatment and rifampin-RIP treatment.
g
P < 0.05 versus levofloxacin treatment.